+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biodefense Market Size, Share & Trends Analysis Report By Product (Anthrax, Small Pox, Botulism, Radiation/Nuclear), By Region (North America, Latin America, Europe, Asia Pacific, MEA), And Segment Forecasts, 2019 - 2025

  • ID: 4764579
  • Report
  • Region: Asia, Asia Pacific, Europe, North America, United States
  • 125 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • Achaogen, Inc
  • B.Ichor Medical Systems
  • Bavarian Nordic
  • Cleveland Biolabs
  • Elusys Therapeutics, Inc.
  • Nanotherapeutics, Inc.
  • MORE
The global biodefense market size is expected to reach USD 6.50 billion by 2025, growing at a CAGR of 4.5% over the forecast period. The market is majorly driven by rising focus of the public agencies on mitigating the risk of Chemical, Biological, Radiological and Nuclear (CBRN) threats and increased funding for biodefense. Biomedical Advanced Research and Development Authority (BARDA), National Interagency Confederation for Biological Research (NICBR), and National Institute of Allergy and Infectious Diseases (NIAID) are major organizations that provide financial support for biodefense research and stockpiling in U.S.

Ongoing research for the development of vaccinations and anti-toxins against biological threats, such as Zika virus, is also one of the key drivers contributing to the market growth. For instance, Ohio State University is undertaking a progressive research to develop a vaccine against the Zika virus that has proven beneficial results in the mice models. According to a survey, in Brazil, around 2,952 confirmed cases of Zika-related microcephaly in newborns were reported. Thus, rising risk of biological threats and subsequently rising R&D funding are augmenting the growth of this market.

Presence of EUA policy in U.S. is also positively impacting the market growth. The EUA policy empowers FDA Commissioners to allow and authorize the usage of a medical product(s) for commercial use, at the time of a declared emergency in the country posing a threat to public health, that are currently unapproved or an application of an approved medical product for a particular indication is unapproved by the FDA. The government agencies issued the EUA policy for antiviral drugs to fight against diseases, such as Zika virus infection and swine flu.

Further key findings from the study suggest:
  • Anthrax held the largest share in 2018 owing to increased investments by government agencies and collaborations between public and private companies to develop and stockpile anthrax vaccines
  • Others segment consists of chemical and biological products. It accounted for the second-largest revenue share in 2018
  • Small pox is expected to be the fastest-growing product segment of the global biodefense market over the forecast period
  • North America was the largest regional market owing to favorable government initiatives and funding in the field of biodefense
  • Europe is expected to witness the maximum growth rate from 2019 to 2025 on account of growing focus of the European countries to enhance the preparedness against CBRN threats
  • Some of the key companies in the global market include PharmAthene, Inc.; Emergent BioSolutions, Inc.; SIGA Technologies, Inc.; and Xoma Corporation


Please Note: This report will be delivered within 2 business days of ordering.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Achaogen, Inc
  • B.Ichor Medical Systems
  • Bavarian Nordic
  • Cleveland Biolabs
  • Elusys Therapeutics, Inc.
  • Nanotherapeutics, Inc.
  • MORE
Chapter 1 Research Methodology
1.1 Market Segmentation & Scope
1.2 Market Definition
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 Internal database
1.3.3 Secondary sources & third party perspectives
1.3.4 Primary research:
1.4 Information Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Data Visualization
1.6 Data Validation & Publishing

Chapter 2 Executive Summary
2.1 Biodefense Market Outlook, 2014 - 2025 (USD Million)
2.2 Biodefense Segment Outlook, 2014 - 2025 (USD Million)
2.3 Biodefense Competitive Insights Outlook, 2014 - 2025 (USD Million)

Chapter 3 Biodefense Market Variables, Trends & Scope
3.1 Biodefense Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Related/ancillary market outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis
3.4 User Perspective Analysis
3.4.1 End-user behaviour analysis
3.4.2 Market influencer analysis
3.5 List of Key End-users
3.6 Technology Overview
3.6.1 Technology timeline
3.7 Regulatory Framework
3.7.1 Standards and compliances
3.8 Biodefense Market Dynamics
3.8.1 Market driver analysis
3.8.2 Market restraint analysis
3.8.3 Industry challenges
3.9 Biodefense Market Analysis Tools
3.9.1 Industry analysis - Porter’s
3.9.1.1 Supplier power
3.9.1.2 Buyer power
3.9.1.3 Substitution threat
3.9.1.4 Threats from new entrant
3.9.1.5 Competitive rivalry
3.9.2 PESTEL analysis
3.9.2.1 Political landscape
3.9.2.2 Enviornmental landscape
3.9.2.3 Social landscape
3.9.2.4 Technology landscape
3.9.2.5 Economic landscape
3.9.2.6 Legal landscape
3.9.3 Major deals & strategic alliances analysis
3.9.3.1 Joint ventures
3.9.3.2 Mergers & acquisitions
3.9.3.3 Strategic partnerships
3.9.4 Market entry strategies

Chapter 4 Biodefense Market- Competitive Analysis
4.1 Recent developments & impact analysis, by key market participants
4.2 Company/Competition Categorization
4.3 Vendor Landscape
4.3.1 Key Customers
4.3.2. Funding outlook
4.4 Public Companies
4.4.1 Company market position analysis
4.4.2 Company ranking, by region
4.5 Private Companies
4.5.1 List of key emerging companies /technology disruptors/innovators
4.5.2 Regional network map
4.5.3 Company market position analysis

Chapter 5 Biodefense Market: Product Estimates & Trend Analysis
5.1 Definition & Scope
5.2 Product Market Share Analysis, 2018 & 2025
5.3 Segment Dashboard
5.4 Global Biodefense Market Revenue Estimates and Forecasts, by Product, 2014 - 2025 (USD Million)
5.4.1 Anthrax
5.4.1.1 Anthrax market revenue estimates and forecasts, 2014 - 2025 (USD Million)
5.4.2 Small pox
5.4.2.1 Small Pox Market revenue estimates and forecasts, 2014 - 2025 (USD Million)
5.4.3 Botulism
5.4.3.1 Botulism market revenue estimates and forecasts, 2014 - 2025 (USD Million)
5.4.4 Radiation/Nuclear Defense
5.4.4.1 Radiation/nuclear defense market revenue estimates and forecasts, 2014 - 2025 (USD Million)
5.4.5 Others
5.4.5.1 Others market revenue estimates and forecasts, 2014 - 2025 (USD Million)

Chapter 6 Biodefense Market: Regional Estimates & Trend Analysis, By Product
6.1 Regional Biodefense Market Snapshot, 2018 & 2025 (market size, CAGR, top verticals, top trends)
6.2 Leading Players, by Region, 2018
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East & Africa
6.3 North America
6.3.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.3.2 U.S.
6.3.2.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.3.3 Canada
6.3.3.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.4 Europe
6.4.1. Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.4.2 U.K.
6.4.2.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.4.3 Germany
6.4.3.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.4.4 France
6.4.4.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.4.5 Spain
6.4.5.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.4.6 Italy
6.4.6.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.4.7 Russia
6.4.7.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.5 Asia Pacific
6.5.1. Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.5.2 Japan
6.5.2.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.5.3 China
6.5.3.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.5.4 India
6.5.4.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.5.5 Australia
6.5.5.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.5.6 Singapore
6.5.6.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.5.7 South Korea
6.5.7.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.6 Latin America
6.6.1. Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.6.2 Brazil
6.6.2.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.6.3 Mexico
6.6.3.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.6.4 Argentina
6.6.4.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.7 MEA
6.7.1. Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.7.2 South Africa
6.7.2.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.7.3 Saudi Arabia
6.7.3.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.7.4 UAE
6.7.4.1 Market revenue estimates and forecasts, by product, 2014 - 2025 (USD Million)
6.8 SWOT Analysis, by Factor
6.8.1 North America
6.8.2 Europe
6.8.3 Asia Pacific
6.8.4 Latin America
6.8.5 Middle East & Africa

Chapter 7 Competitive Landscape
7.1 Company Profiles
7.1.1 Xoma Corporation
7.1.1.1 Company overview
7.1.1.2 Financial performance
7.1.1.3 Product benchmarking
7.1.1.4 Strategic initiatives
7.1.2 Altimune, Inc. (PharmAthene, Inc.)
7.1.2.1 Company overview
7.1.2.2 Financial performance
7.1.2.3 Product benchmarking
7.1.2.4 Strategic initiatives
7.1.3 Emergent Biosolutions Inc.
7.1.3.1 Company Overview
7.1.3.2 Financial Performance
7.1.3.3 Product Benchmarking
7.1.3.4 Strategic Initiatives
7.1.4 Dynavax Technologies Corporation
7.1.4.1 Company overview
7.1.4.2 Financial performance
7.1.4.3 Product benchmarking
7.1.4.4 Strategic initiatives
7.1.5 SIGA Technologies, Inc.
7.1.5.1 Company Overview
7.1.5.2 Financial Performance
7.1.5.3 Product Benchmarking
7.1.5.4 Strategic Initiatives
7.1.6 Elusys Therapeutics, Inc.
7.1.6.1 Company Overview
7.1.6.2 Financial Performance
7.1.6.3 Product Benchmarking
7.1.6.4 Strategic Initiatives
7.1.7 B.Ichor Medical Systems
7.1.7.1 Company overview
7.1.7.2 Financial performance
7.1.7.3 Product benchmarking
7.1.7.4 Strategic initiatives
7.1.8 Dynport Vaccine Company LLC
7.1.8.1 Company overview
7.1.8.2 Financial performance
7.1.8.3 Product benchmarking
7.1.8.4 Strategic initiatives
7.1.9 Cleveland Biolabs
7.1.9.1 Company overview
7.1.9.2 Financial performance
7.1.9.3 Product benchmarking
7.1.9.4 Strategic initiatives
7.1.10 Bavarian Nordic
7.1.10.1 Company overview
7.1.10.2 Financial performance
7.1.10.3 Product benchmarking
7.1.10.4 Strategic initiatives
7.1.11 Achaogen, Inc
7.1.11.1 Company overview
7.1.11.2 Financial performance
7.1.11.3 Product benchmarking
7.1.11.4 Strategic initiatives
7.1.12 Nanotherapeutics, Inc.
7.1.12.1 Company overview
7.1.12.2 Financial performance
7.1.12.3 Product benchmarking
7.1.12.4 Strategic initiatives
7.1.13 Alnylam Pharmaceuticals, Inc.
7.1.13.1 Company overview
7.1.13.2 Financial performance
7.1.13.3 Product benchmarking
7.1.13.4 Strategic initiatives
7.2 List of other companies

*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Xoma Corporation
  • Altimune, Inc. (PharmAthene, Inc.)
  • Emergent Biosolutions Inc.
  • Dynavax Technologies Corporation
  • SIGA Technologies, Inc.
  • Elusys Therapeutics, Inc.
  • B.Ichor Medical Systems
  • Dynport Vaccine Company LLC
  • Cleveland Biolabs
  • Bavarian Nordic
  • Achaogen, Inc
  • Nanotherapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4764579
Adroll
adroll